These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 10551684)
21. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
22. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Topol EJ; Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410 [TBL] [Abstract][Full Text] [Related]
23. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. Feldman DN; Wong SC; Bergman G; Minutello RM J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400 [TBL] [Abstract][Full Text] [Related]
24. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148 [TBL] [Abstract][Full Text] [Related]
25. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Ibbotson T; McGavin JK; Goa KL Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074 [TBL] [Abstract][Full Text] [Related]
26. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ; JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372 [TBL] [Abstract][Full Text] [Related]
27. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. Svensson L; Aasa M; Dellborg M; Gibson CM; Kirtane A; Herlitz J; Ohlsson A; Karlsson T; Grip L Am Heart J; 2006 Apr; 151(4):798.e1-7. PubMed ID: 16569536 [TBL] [Abstract][Full Text] [Related]
28. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction. Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517 [TBL] [Abstract][Full Text] [Related]
29. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
30. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. Campbell KR; Ohman EM; Cantor W; Lincoff AM Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178 [TBL] [Abstract][Full Text] [Related]
31. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schömig A; JAMA; 2004 Feb; 291(8):947-54. PubMed ID: 14982910 [TBL] [Abstract][Full Text] [Related]
32. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty]. Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204 [TBL] [Abstract][Full Text] [Related]
33. Triple therapy for acute myocardial infarction: combining fibrinolysis, platelet IIb/IIIa inhibition, and percutaneous coronary intervention. Herrmann HC Am J Cardiol; 2000 Apr; 85(8A):10C-6C. PubMed ID: 10793175 [TBL] [Abstract][Full Text] [Related]
34. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction. Gum PA; Lincoff AM Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942 [TBL] [Abstract][Full Text] [Related]
35. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Lincoff AM; Califf RM; Topol EJ J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948 [TBL] [Abstract][Full Text] [Related]